Peptides are Nature's most diverse toolkit and fulfill a plethora of functions, ranging from hormonal to antimicrobial activities.^[@ref1]^ In the past decade, especially cyclic peptides have attracted increased attention as a highly promising class of therapeutics.^[@ref2]−[@ref4]^ Key features of macrocylic peptides include increased metabolic stability and improved binding affinity, compared to linear molecules.^[@ref5]^ The set of macrocycles in nature ranges from small monocyclic to highly constrained multicyclic peptides such as cyclotides^[@ref6],[@ref7]^ or the "last-resort" antibiotic vancomycin, which is a prime example of a multicyclic peptide drug.^[@ref8],[@ref9]^ While Nature produces these complex, highly constrained, multicyclic compounds in a relatively straightforward manner using cascades of enzyme-catalyzed reactions, their chemical synthesis is often elaborate resulting in low overall yields.^[@ref10]^ Clearly, there is a need to overcome these challenges by the development of novel synthetic methodologies. Thanks to their inherent properties, such as excellent regioselectivity and stereoselectivity, the use of enzymes has recently gained increased attention as a tool for peptide head-to-tail cyclization. Enzymes such as omniligase-1, butelase, or sortase^[@ref11]−[@ref13]^ have been successfully employed for this purpose.^[@ref14]^ For example, omniligase-1 efficiently catalyzes head-to-tail cyclization of linear *C*-terminal glycolate-ester peptides in aqueous solution.^[@ref11],[@ref15]^ In addition, peptide cyclization using small molecule organic scaffolds has been widely explored. For example, CLIPS technology (Chemical Linkage of Peptides onto Scaffolds)^[@ref16]^ is used for peptide cyclization in vitro and for the generation of large phage-displayed libraries of thioether-bridged bicyclic peptides.^[@ref16]−[@ref20]^ However, despite its ease, the applicability is limited to the preparation of monocyclic and bicyclic peptides.

Recently, our group introduced a novel concept to expand the CLIPS technology to furnish tricyclic and tetracyclic peptides via a one-pot procedure, by combining it with two orthogonal ligation methods: Cu(I)-catalyzed alkyne--azide cycloaddition (CuAAC) and enzymatic head-to-tail cyclization using omniligase-1 (chemo-enzymatic peptide synthesis, CEPS).^[@ref11],[@ref21]^ Here, we present a successful expansion of the set, utilizing oxime ligation. This well-established orthogonal ligation method involves the condensation reaction between an aminooxy group and a carbonyl electrophile.^[@ref22]−[@ref25]^ In contrast to CuAAC, the formed oxime bond shows *E*/*Z* isomerism, which is influenced by their substituents.^[@ref26]^

To explore the combination of CEPS, CLIPS, and oxime ligation, a novel type of small-molecule scaffold was developed, comprising two reactive primary bromides (CLIPS) in combination with either (a) an aldehyde or (b) an aminooxy. Both the aminooxy and aldehyde were chemically protected (with Boc and diethyl-acetal groups) and are only liberated after the initial CLIPS reaction to ensure a controlled, regioselective cyclization. CEPS cyclization followed by CLIPS and subsequently oxime ligation was envisaged the most straightforward approach, based on previous experience.^[@ref21]^ For oxime ligation, the peptide contains either (a) the aminooxy or (b) the ketone moiety. Therefore, we set out to investigate two different strategies ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). For Strategy I, the peptide bears the aminooxy functionality, with the scaffold (**T4-2**(C=O)/**T4-3**(C=O)) bearing the aldehyde, ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a), while Strategy II features a reversed orientation of the aminooxy and ketone moieties (**T4-1**(ONH~2~)/**T4-2**(ONH~2~)/**T4-3**(ONH~2~)) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b). The set of scaffolds we studied comprises the rigid **T4-1**(ONH~2~)^[@ref27]^ and the flexible scaffolds **T4-2**(ONH~2~)/**T4-2**(C=O) and **T4-3**(C=O)/**T4-3**(ONH~2~), all containing rotatable amide bonds in combination with a bromoacetamide.^[@ref28]^ \[For the synthesis of the scaffolds, see the [Supporting Information (SI)](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf).\]

![Schematic representation of the CEPS/CLIPS/oxime cyclizations and the evaluated scaffold and peptides: (a) aminooxy-bearing peptides with scaffolds **T4-2**(C=O)/**T4-3**(C=O) (Strategy I); (b) peptides comprising ketone-functionalized amino acids in combination with scaffolds **T4-1**(ONH~2~)/**T4-2**(ONH~2~)/**T4-3**(ONH~2~) (Strategy II), for the synthesis of tetracyclic peptides; and (c) peptide codes and the corresponding sequences.](ol-2019-00378b_0001){#fig1}

In Strategy I, the aminooxy residue is introduced in the form of aminooxy-homoserine (**hS**(ONH~2~)),^[@ref26]^ whereas in Strategy II, two different keto-amino acids, namely *para*-acetyl phenylalanine (**F**(C=O)), being well-studied^[@ref29]−[@ref33]^ and a *tert*-butyl ketone derivative of aspartic acid (**D**(C=O)), were incorporated into the peptide, respectively. In Strategy I ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a), scaffold aldehydes are used, presumably resulting in *E*-configured oximes only. In contrast, Strategy II ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b) starts from the keto-containing amino acids **F**(C=O) and **D**(C=O); hence, a mixture of *E*/*Z*-oximes may be expected, with an increased preference for the *E*-isomer (**D**(C=O) \> **F**(C=O)), because of the steric hindrance of the *^t^*Bu group.

In order to thoroughly investigate the combination of CEPS, CLIPS, and oxime ligation for the preparation of tetracyclic peptides, a library of eight peptides containing different numbers of amino acids (*n*) between the CLIPS and oxime junction points (*n* = 3, 4, 5) was designed ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c). The synthesis of peptides containing both the *C*-terminal glycolate-type ester, as required for the CEPS macrolactamization,^[@ref15]^ and the protected aminooxy/ketone amino acids, was performed using classical automated SPPS (see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)). Generally, the ketone-containing peptides were easier to obtain (little to no side reactions) than peptides containing amino acid **hS**(ONH~2~), of which the latter often resulted in a low-yielding synthesis and troublesome purifications. Common side-reactions included isopropylidene formation of the aminooxy functionality with traces of acetone, incomplete SPPS-coupling of Fmoc-**hS**(ONHBoc)--OH, and elimination of the aminooxy moiety.^[@ref34]^ Peptides containing **D**(C=O) exhibited low solubility in aqueous solutions, potentially requiring the addition of solubilizing agents (e.g., urea) for efficient enzymatic cyclization. Nevertheless, all linear peptide Cam-esters (*n* = 3, 4, 5) were efficiently head-to-tail cyclized using omniligase-1 (\>85% average efficiency; see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)). Initially, we explicitly avoided placing one of the oxime-reactive noncanonical amino acids, **hS**(ONH~2~), **F**(C=O), **D**(C=O), in the enzymatic recognition sequence of the peptide (N-terminal P1′ and P2′ and C-terminal P4--P1)^[@ref35]^ in order to ensure a high cyclization efficiency. However, it turned out that all three amino acids were well-tolerated at the majority of positions (**F**(C=O) = all pockets; **hS**(ONH~2~) = P3, P2, P1′, P2′, **D**(C=O) = P3, P2; see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)), despite distinct differences in reaction rate that could, in turn, be compensated for by adding an increased amount of biocatalyst. Generally, these results demonstrate the broad applicability and compatibility of the CEPS cyclization, even when using noncanonical amino acids.

Next, we explored the CLIPS and oxime ligation reactions using the scaffolds given in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}. Generally, CLIPS reactions with the monocyclic peptides proceeded cleanly under standard reaction conditions (0.5 mM peptide solution, ∼0.9 equiv of scaffold), aqueous NH~4~HCO~3~ solution (pH \>8.0), within 20 min at room temperature (rt)) to give the corresponding bicyclic products (see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)). This was followed by deprotection of the scaffolds for oxime ligation. For Strategy I, the acetals in **T4-2**(C=O)/**T4-3**(C=O) were hydrolyzed by the addition of a 15% (v/v) aqueous TFA solution. Under these conditions, oxime ligation occurs instantaneously. For Strategy II, Boc-removal to liberate the aminooxy moiety of **T4-1**(ONH~2~)/**T4-2**(ONH~2~)/**T4-3**(ONH~2~) was performed after lyophilization of the CLIPSed bicycle, by the addition of trifluoroacetic acid in dichloromethane (2:1, v/v). The peptide was dried in vacuo before oxime ligation was instigated in aqueous dimethylsulfoxide (DMSO) (0.5 mM, 16 h at 40 °C). Reactions were monitored via UPLC analysis (column temperature = 50 °C).

Following these generalized procedures, we first investigated the reaction of **hS**(ONH~2~)-containing monocyclic hexadecapeptides with scaffolds **T4-2**(C=O) and **T4-3**(C=O) (Strategy I, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). The CLIPS reactions, yielding the bicyclic peptides, went smoothly (see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)). For the oxime ligation, these peptide--scaffold combinations are the least hindered as it contains the aldehyde, which, in principle, should solely yield the *E*-isomer upon oxime ligation. Both tetracycles c**1**~3333~-**hS**(ONH~2~)**·T4-2**(C=O)^c/o^ and c**1**~3333~-**hS**(ONH~2~)**·T4**-**3**(C=O)^c/o^ were formed as a mixture of two different products (*t*~R~ = 0.82/0.83 min and *t*~R~ = 0.70/0.72 min) with identical molecular weights. This can likely be attributed to hindered rotation around either the aryl-C(=O) or the HN-C=O bond in the scaffolds, as a result of the relatively small peptide ring size ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a and [2](#fig2){ref-type="fig"}d), matching earlier observations.^[@ref21]^ Separation of the products was not attempted and was deemed impossible, because the isomerism is considered conformational, rather than configurational, assuming both products are in thermodynamic equilibrium. This assumption was confirmed by the fact that, for c**1**~3333~-**hS**(ONH~2~)**·T4-3**(C=O)^c/o^, a third isomer was initially observed at *t*~R~= 0.73 min, that disappeared overnight at rt.

![UPLC traces of Strategy I oxime ligations with **hS**(ONH~2~)-containing bicyclic peptides (*n* = 3, 4, 5) with scaffolds (a--c) **T4-3**(C=O) and (d--f) **T4-2**(C=O). Peak masses: M1 = first encountered peak (tetracycle); M2, etc. = peaks with longer *t*~R~.](ol-2019-00378b_0002){#fig2}

Interestingly, an increased loopsize (*n* = 4) in the cyclic 20-peptide led to the formation of two broad product peaks for the tetracyclic constructs c**4**~4444~**hS**(ONH~2~)**·T4**-**2**(C=O)^c/o^ and c**4**~4444~**hS**(ONH~2~)**·T4**-**3**(C=O)^c/o^ (see [Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b and [2](#fig2){ref-type="fig"}e). We attribute this peak broadening to slow equilibration between several conformers on UPLC time scale, en route to coalescence, while being comparatively faster than the c**1**~3333~**hS**(ONH~2~) tetracycles. Finally, for the largest 24-membered peptides c**6**~5555~-**hS**(ONH~2~)**·T4**-**2**(C=O)^c/o^ and c**6**~5555~-**hS**(ONH~2~)**·T4**-**3**(C=O)^c/o^, the UPLC clearly shows a single product (see [Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c and [2](#fig2){ref-type="fig"}f), confirming that conformational isomers in these macrocycles are in rapid equilibrium at the UPLC-time scale. This is consistent with previous findings that the number of product isomers obtained is linearly correlated to the difference in peptide lengths and attributable to conformational/rotational rather than configurational/structural isomers.^[@ref21]^

Because oxime formation within the systems studied for Strategy II ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b) starts from ketones, *E*/*Z* mixtures may arise. Although intermolecular oxime formation between linear peptides containing two **F**(C=O) residues with methoxyamine or benzylhydroxylamine gave only single products, the prediction of the precise *E*/*Z* pattern of more-constrained constructs remains challenging. Interestingly, in contrast to Strategy I, not the peptide length appeared to be critical for the isomer distribution, but the type of scaffold, either **T4-1**(ONH~2~), **T4-2**(ONH~2~), or **T4-3**(ONH~2~), did seem to have an effect ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

![UPLC chromatograms of Strategy II oxime ligations with **F**(C=O) peptides and scaffolds **T4-1**(ONH~2~)/**T4-2**(ONH~2~)/**T4-3**(ONH~2~) reacted for 16 h at 40 °C. Peak masses: M1= first encountered peak (tetracycle); M2, etc.= peaks with longer *t*~R~.](ol-2019-00378b_0003){#fig3}

Using scaffold **T4-1**(ONH~2~) resulted in the formation of four products for all peptide lengths ([Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a--c). This was innate to the scaffold, since the quaternary ammonium center is prochiral. Upon peptide ligation in an unfavorable manner, there is no rotational relaxation of the system, yielding two isomers, which do not exchange within a time frame of one month. When using scaffold **T4-2**(ONH~2~), we did not observe thermodynamic equilibration, but obtained the product with 2--4 different isomers, depending on the specific peptide used (see [Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}d--f). For example, in the case of c**5**~4444~-**F**(C=O)**·T4**-**2**(ONH~2~)^c/o^ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}e), two distinct products were formed, that proved thermodynamic stability and did not interconvert upon separation of both peaks. In contrast, at elevated temperatures (40 °C), c**2**~3333-~**F**(C=O)**·T4**-**3**(ONH~2~)^c/o^ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}g) forms one thermodynamic product from initially four isomers. For c**5**~4444~-**F**(C=O)**·T4**-**3**(ONH~2~)^c/o^, however, very close running products were obtained and could only be separated using a slow eluting UPLC gradient ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}h). Lastly, c**7**~5555~-**F**(C=O)**·T4**-**3**(ONH~2~)^c/o^ instantaneously yields a single product ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}i), suggesting that larger cycles might also result in the formation of a single product.

Since the *n* = 4 peptides were chosen based on the sequence of a previously published tetracyclic peptide,^[@ref21]^ we opted to compare the structure of c**5**~4444~-**F**(C=O)**·T4**-**2**(ONH~2~)^c/o^ with the NMR structure of the identical peptide fused with a **T4**~**2**~ scaffold.^[@ref21],[@ref36]^ However, NMR studies revealed that the tetracyclic structure of c**5**~4444~-**F**(C=O)**·T4**-**2**(ONH~2~)^c/o^ is present in many different conformations, because of hindered rotation around the scaffold's amide bond, as well as a slow equilibrium of the *E*/*Z* oxime bond. This prevented a detailed structure determination of the scaffold (see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)).

Similar to **F**(C=O), **D**(C=O) also contains an asymmetric ketone. However, because of the bulky *tert*-butyl group, it is expected that oxime ligation occurs selectively at one face of the ketone only, thus yielding single-isomeric products. Initial experiments with methoxyamine revealed that the free amino acid is fairly unreactive and intermolecular reactions took weeks to complete. On the other hand, intramolecular reactions are much faster, yet slower, compared to **F**(C=O). Since **D**(C=O) is very apolar and poorly reactive, only the most divisive loop lengths (c**3**~3333~-**D**(C=O) and c**8**~5555~-**D**(C=O)) were investigated ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The reactivity of both peptides is quite similar and for all scaffolds (**T4--1**(ONH~2~) to **T4--3**(ONH~2~)), a single main product was obtained, which was especially surprising in the case of scaffold **T4-1**(ONH~2~) (see [Figures [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a and [4](#fig4){ref-type="fig"}b). However, all reactions did not go to completion and mono-oximed products were still present after several weeks. It seems that only thermodynamically favorable tetracycles are formed, and unfavorable conformations of the mono-oxime do not react further. Clearly, the gain of selectivity comes at the cost of the reaction rate, but is the only system with consistent single-peak results of the tetracyclic peptide for all peptide/scaffold combinations.

![UPLC chromatograms of Strategy II oxime ligations with **D**(C=O) peptides and scaffolds **T4-1**(ONH~2~)/**T4-2**(ONH~2~)/**T4-3**(ONH~2~) reacted for 16 h at 40 °C. Peak masses: M1= first encountered peak (tetracycle); M2, etc. = peaks with longer *t*~R~. \[Legend: (★) mono-oxime still present; (●) disulfide starting material not reacted during CLIPS.\]](ol-2019-00378b_0004){#fig4}

To conclude, we have devised a regioselective preparation of tetracyclic peptides using a combination of CEPS, CLIPS, and oxime ligation. Most tetracyclic peptides were obtained as single isomers, depending on the peptide length and scaffold used. For **hS**(ONH~2~)-containing peptides, two conformational isomers were obtained for short sequences emerging from hindered rotation. For **F**(C=O)-containing peptides, also thermodynamically stable isomers were found arising from oxime *E*/*Z* configurational mixtures. Although oxime *E*/*Z* mixture formation was not observed with the sterically demanding ketone in amino acid **D**(C=O), its low reactivity hampers the applicability. Overall, our work that is based on three orthogonal macrocyclization reactions gives regioselective access to tetracyclic peptides. Further studies are in progress to perform the CEPS/CLIPS/oxime sequence in an automated fashion for applications in drug discovery.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.orglett.9b00378](http://pubs.acs.org/doi/abs/10.1021/acs.orglett.9b00378).Detailed procedures for the synthesis of amino acids, peptides, and the scaffolds are given, accompanied by the characterization data (including NMR spectra); procedures and results of all peptide cyclization reactions, including CEPS, CLIPS, and oxime ligation ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b00378/suppl_file/ol9b00378_si_001.pdf)).
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